Aurinia Pharmaceuticals Inc.
AUPH
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.1B
$16.08
▼ -0.25%
P/E
6.96
Mkt Cap
$2.1B
52-Wk Range
$10.34–$19.25
52-Week Range
$10.34 - $19.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 30.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- FDA-approved LUPKYNIS with first-in-class mechanism for lupus nephritis
- Strategic partnership with Otsuka Pharmaceutical for global distribution and resources
- Focused expertise in autoimmune and kidney disease therapeutics
- Established commercial infrastructure and market presence in the US
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Expanding LUPKYNIS market penetration and patient adoption in lupus nephritis
Value
Attractively priced below Biotech & Therapeutics peer average
Momentum
Stable
+2.7% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AUPH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 6, 2026
Reported EPS of $0.28 vs $0.24 consensus (+16.7% surprise). Revenue of $83.2M vs $80.4M expected (+3.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+16.7%
Revenue trend · last 8Q
—
+33%
+24%
+22%
+8%
+29%
+24%
+19%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$67.8M
$59.9M
$62.5M
$70.0M
$73.5M
$77.1M
$77.7M
$83.2M
Margins · last 8Q
Gross
92.1%
Operating
55.7%
Profit
45.0%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Aug 7, 2026
vs Industry
How AUPH stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related